Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04373603
Other study ID # 2020-0573
Secondary ID A539730SMPH/SURG
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date July 2022
Est. completion date July 2023

Study information

Verified date July 2022
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall purpose of this study is to evaluate the safety and efficacy of co-administration of tranexamic acid (TXA) with hyaluronic acid (HA) in reducing swelling, bruising and pain after facial injection. This will be done by comparing HA to HA+TXA in participants undergoing facial filler injections. Patients undergoing facial filler injections almost always have the same type of injection performed bilaterally in order to maintain symmetry. This provides a unique opportunity where participants can serve as their own controls. Participants will be injected with HA on half of their face and the other half of the face will be injected with HA+TXA. Swelling, bruising, pain, and overall satisfaction will be assessed using participant self-reported surveys, physician surveys, and review of medical records.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date July 2023
Est. primary completion date July 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - Age equal to or greater than 18 but less than or equal to 89 years. - Medically appropriate to undergo elective facial filler injection at UW Health by principal investigator - English speaking Exclusion Criteria: - Minors or under the age of 18 - Patient over the age of 89 - Pregnant or breast-feeding women - Individuals unable to give consent due to another condition such as impaired decision-making capacity. - Participants with a history of a thrombotic event (DVT, PE, stroke, MI) or genetic disorder that increases risk of thrombosis - Concurrent use of estrogen - Participant undergoing unilateral facial filler injections - Participants with history of hypersensitivity to TXA or any of the other ingredients - Participants that are on current therapeutic anticoagulation therapy - Participants with stage 2 or greater renal failure - Participants on hemo- or peritoneal dialysis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tranexamic acid
TXA is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, thus inhibiting degradation of fibrin clots and serving as an antifibrinolytic
Other:
Saline
sodium chloride and water for use as control
Drug:
Hyaluronic acid
Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue

Locations

Country Name City State
United States University of Wisconsin School of Medicine and Public Health Madison Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intensity of Bruising Score Participant reported intensity of bruising score on a 5 point Likert scale where 1 is no bruising and 5 is severe bruising. Post procedure day 7
Secondary Intensity of Bruising Score Participant reported intensity of bruising score on a 5 point Likert scale where 1 is no bruising and 5 is severe bruising. Post procedure day 1
Secondary Intensity of Bruising Score Participant reported intensity of bruising score on a 5 point Likert scale where 1 is no bruising and 5 is severe bruising. Post procedure day 30
Secondary Intensity of Swelling Score Participant reported intensity of swelling score on a 5 point Likert scale where 1 is no swelling and 5 is severe swelling. Post procedure day 1
Secondary Intensity of Swelling Score Participant reported intensity of swelling score on a 5 point Likert scale where 1 is no swelling and 5 is severe swelling. Post procedure day 7
Secondary Intensity of Swelling Score Participant reported intensity of swelling score on a 5 point Likert scale where 1 is no swelling and 5 is severe swelling. Post procedure day 30
Secondary Pain Score Participants will rate their pain on a scale of 0-10 where 0 is no pain and 10 is the highest pain. Post procedure day 1
Secondary Pain Score Participants will rate their pain on a scale of 0-10 where 0 is no pain and 10 is the highest pain. Post procedure day 7
Secondary Pain Score Participants will rate their pain on a scale of 0-10 where 0 is no pain and 10 is the highest pain. Post procedure day 30
Secondary Participant Satisfaction Score Participants will rate their satisfaction on a 5 point Likert scale where 1 is completely dissatisfied and 5 is completely satisfied. Post procedure day 1
Secondary Participant Satisfaction Score Participants will rate their satisfaction on a 5 point Likert scale where 1 is completely dissatisfied and 5 is completely satisfied. Post procedure day 7
Secondary Participant Satisfaction Score Participants will rate their satisfaction on a 5 point Likert scale where 1 is completely dissatisfied and 5 is completely satisfied. Post procedure day 30
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05109000 - Comparison of Subcutaneous Injection of Normal Saline and Bacteriostatic Saline Phase 4
Completed NCT05577832 - Testing Different Methods of Intramuscular Injection N/A
Completed NCT03645369 - Effectiveness of Mechano-Analgesia and Cold Application on Ecchymosis, Pain and Satisfaction at Subcutaneous Heparin Injection N/A
Completed NCT05771285 - Cold Application on the Subcutaneous Injection N/A